{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["talazoparib","avelumab"]],"indication":"STK11-mutated advanced non-squamous non-small cell lung cancer","name":"LUNG-MAP","nct_id":"NCT04173507","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lung-map-nct04173507. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Treatment (talazoparib, avelumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2024-05-01","type":"ACTUAL"},"conditions":["Advanced Lung Non-Squamous Non-Small Cell Carcinoma","Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":{"count":47,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Avelumab","otherNames":["Bavencio","MSB-0010718C","MSB0010718C"],"type":"DRUG"},{"name":"Talazoparib","otherNames":["BMN 673","BMN-673"],"type":"DRUG"},{"name":"Talazoparib Tosylate","otherNames":["Talzenna"],"type":"DRUG"}],"last_update":"2024-09-03","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-11-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"From date of registration to progression or treatment discontinuation, up to 1 year and 9 months"},{"measure":"Disease Control Rate at 12 Weeks (DCR12)","timeFrame":"12 weeks after registration"}],"references":[],"start_date":{"date":"2020-02-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","url":"https://clinicaltrials.gov/study/NCT04173507"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lung-map-nct04173507"}